The FDA approved atezolizumab (Tecentriq, Genentech) for adjuvant treatment after resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have programmed death-ligand 1 (PD-L1) expression on 1% or more of tumor cells, as determined by an FDA-approved test.
The agency also approved the VENTANA PD-L1 (SP263) Assay (Ventana) as a companion diagnostic device to select patients with NSCLC for adjuvant treatment with